|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
SELECT PUBLICATIONS
Burstein HJ et al. Dose-dense nab-paclitaxel (nanoparticle albumin-bound paclitaxel) in adjuvant chemotherapy for breast cancer: A feasibility study. Proc ASCO 2007;Abstract 594.
Gradishar W et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). Proc ASCO 2007;Abstract 1032.
Gradishar WJ. Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother 2006a;7(8):1041-53. Abstract
Gradishar W et al. A randomized phase 2 trial of qw or q3w ABI-007 (ABX) vs. q3W solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC). Presentation. San Antonio Breast Cancer Symposium 2006b;Abstract 46.
Gradishar W et al. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: First results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. San Antonio Breast Cancer Symposium 2006c;Abstract 12.
Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract
Henderson IC, Bhatia V. Nab-paclitaxel for breast cancer: A new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther 2007;7(7):919-43. Abstract
Ibrahim NK et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005;23(25):6019-26. Abstract
Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast Cancer Symposium 2005;Abstract 3.
Sledge G et al. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. Proc ASCO 2007;Abstract 1013.
Vahdat L et al. Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes. Proc ASCO 2007;Abstract 1006.
 |
 |
EDITOR'S NOTE
Peto’s curse
Neil Love, MD
- Select publications
INTERVIEWS
George W Sledge Jr, MD
- Select publications
William J Gradishar, MD
- Select publications
Lee S Schwartzberg, MD
- Select publications
FACULTY TUMOR PANEL
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
